Nomura Holdings’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Nomura Holdings’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-416,000	Closed	-$2.49M	–	1977
2022 Q4	$2.49M	Buy	416,000 +316,000	+316%	+$1.72M	0.01%	663
2022 Q3	$583K	Buy	+100,000	New	+$623K	﹤0.01%	1077

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Nomura Holdings's CTIC Position: Q2 2023 in Review

Nomura Holdings sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 85,648 shares — an estimated $360K sold.

Nomura Holdings first reported a position in CTIC in Q2 2013 and held it in 7 quarters. The position peaked at $997K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Nomura Holdings reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Nomura Holdings sold 85,648 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $360K.
Nomura Holdings first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 7 quarters.
Nomura Holdings's CTI BioPharma Corp. (DE) Common Stock position peaked at $997K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Nomura Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.